Coherus' Humira formulation patent challenge rejected by PTAB
The rejection of a petition against a Humira formulation patent is problematic for Coherus but may not affect other adalimumab biosimilar developers, an analyst says.
Archives for November 9, 2016
Selexis and Xencor enter strategic agreement for cell line development
Selexis and Xencor have entered into a strategic agreement which strengthens an existing relationship for multi-specific antibody cell line development
US vaccine programmes set for shake up if Trump sticks to his word
US public health programmes will use lower dose vaccines administered over longer periods from 2017 if President elect Donald Trump adheres to a plan he outlined last year.